JERSEY CITY, N.J.
July 25, 2013
/PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) (the "Company" or "Optimer") today announced it will report second quarter 2013 financial results after the NASDAQ Global Market closes on
Thursday, August 1
. The Company will host a conference call that day at
5:00 p.m. Eastern Time
2:00 p.m. Pacific Time
) to discuss the financial results and highlights for the second quarter and provide a corporate update.
The conference call may be accessed by dialing (877) 280-7280 for domestic callers and +1 (678) 825-8232 for international callers. Please specify to the operator that you would like to join "Optimer's Financial Results Call." The conference call will be webcast live under the Investors section of Optimer's website at
, where it will be archived for 30 days following the call.
About Optimer Pharmaceuticals
We are a global biopharmaceutical company currently focused on commercializing our antibiotic product DIFICID® (fidaxomicin) tablets in
the United States
, and developing other fidaxomicin products in
the United States
and worldwide, both by ourselves and with our partners and licensees. DIFICID, a macrolide antibacterial drug, was approved by the U.S. Food and Drug Administration on
May 27, 2011
, for the treatment of
-associated diarrhea, or CDAD, in adults 18 years of age and older. Fidaxomicin has also received marketing authorization in other jurisdictions, including the European Union, where it is marketed under the trade name DIFICLIR™ by our licensee, Astellas Pharma Europe. CDAD is the most common symptom of
infection, or CDI. Additional information can be found at
Optimer Pharmaceuticals, Inc.
, VP of Investor Relations and Corporate Communications858-964-3418
Jason I. Spark
, Senior Vice President619-849-6005
SOURCE Optimer Pharmaceuticals, Inc.